The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: The VIRTUE study

International Journal of Clinical Practice

Volumn 67, Issue 10, 2013, Pages 957-963

  Al Arouj, M ^a   Hassoun, A A K ^b   Medlej, R ^c   Pathan, M F ^d   Shaltout, I ^e   Chawla, M S ^f   Hristoskova, S ^g   Ditommaso, S ^g   Kadwa, M Y ^g  

^a DASMAN DIABETES INSTITUTE   (Kuwait)

^b Dubai Diabetes Center   (United Arab Emirates)

^c SAINT JOSEPH UNIVERSITY   (Lebanon)

^d BIRDEM Hospital   (Bangladesh)

^e CAIRO UNIVERSITY   (Egypt)

^f India   (India)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADD ON THERAPY; ADULT; AGED; ARTICLE; ASIA; ASTHENIA; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; GLYCEMIC CONTROL; HEADACHE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERHIDROSIS; HYPOGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE EAST; MOSLEM; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PEPTIC ULCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAMADAN; RELIGION; RESTLESSNESS; VOMITING; WEIGHT CONTROL; WEIGHT REDUCTION;

ADAMANTANE; AGED; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; ISLAM; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NITRILES; PROSPECTIVE STUDIES; PYRROLIDINES; SULFONYLUREA COMPOUNDS; WEIGHT LOSS;

EID: 84884980493     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12243     Document Type: Article

References (22)

1. Whiting DR, Guariguata L, Weil C, Shaw J,. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-21.
2. International Diabetes Federation. IDF Diabetes Atlas Update 2012, 5th edn. http://www.idf.org/diabetesatlas/5e/middle-east-and-north-africa (accessed March 2013).
3. Al-Arouj M, Assaad-Khalil S, Buse J, et al. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care 2010; 33: 1895-902.
4. Ibrahim MA,. Managing diabetes during Ramadan. Diabetes Voice 2007; 52: 19-22. http://www.idf.org/sites/default/files/attachments/article-513-en.pdf (accessed March 2013).
5. Hui E, Bravis V, Hassanein M, et al. Management of people with diabetes wanting to fast during Ramadan. BMJ 2010; 340: c3053.
6. Amiel SA, Dixon T, Mann R, Jameson K,. Hypoglycaemia in type 2 diabetes. Diabet Med 2008; 25: 245-54.
7. Salti I, Bénard E, Detournay B, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004; 27: 2306-11.
8. Beshyah SA,. Fasting during the month of Ramadan for people with diabetes: medicine and Fiqh united at last. Ibnosina J Med Biomed Sci 2009; 1: 58-60.
9. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009; 11: 157-66.
10. Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010; 12: 780-9.
11. Hassanein M, Hanif W, Malik W, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin 2011; 27: 1367-74.
12. Devendra D, Gohel B, Bravis V, et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract 2009; 63: 1446-50.
13. Mafauzy M,. Repaglinide versus glibenclamide treatment of type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract 2002; 58: 45-53.
14. Aravind SR, Al Tayeb K, Ismail SB,. et al. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study. Curr Med Res Opin 2011; 27: 1237-42.
15. Ahmed MH, Abdu TA,. Diabetes and Ramadan: an update on use of glycemic therapies during fasting. Ann Saudi Med 2011; 31: 402-6.
16. Al Sifri S, Basiounny A, Echtay A, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract 2011; 65: 1132-40.
17. Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl peptidase-iv inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008; 31: 30-5.
18. Ahren B, Schweizer A, Dejager S, et al. Mechanisms of action of the DPP-4 inhibitor vildagliptin in man. Diabetes Obes Metab 2011; 13: 775-83.
19. Dunning BE, Foley JE, Ahren B,. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005; 48: 1700-13.
20. Christensen M, Vedtofte L, Holst JJ, et al. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 2011; 60: 3103-9.
21. Schweizer A, Foley JE, Kothny W, et al. Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin. Vasc Health Risk Manag 2013; 9: 57-64.
22. Shete AVV,. Real life experience of usage of vildagliptin versus sulphonylurea therapy in fasting patients with type 2 diabetes during Ramadan: an Indian experience [Abstract]. Diabetologia 2011; 54 (Suppl. 1): S342 (Abstract 840).